Lexicon Pharmaceuticals, Inc. (LXRX) · Nov 5, 2026 · Earnings
Beat — EPS -$0.03 vs ~$0.06 loss consensus; revenue $11.25M vs ~$4.15M
Lexicon’s third-quarter earnings beat consensus on a $10 million Novo milestone, while HCM enrollment and the ZYNQUISTA resubmission path remain on track.
Lexicon is transitioning into a cardiometabolic biotech built around sotagliflozin: SONATA-HCM is its main late-stage value driver, ZYNQUISTA is moving toward an FDA resubmission, and Novo is advancing the partnered obesity candidate LX9851. The quarter mostly confirms that plan rather than rewriting it; enrollment completion and the broad patient mix were already largely known before this release.
The reported quarter beat the published bar, mainly because milestone timing landed better than expected. Lexicon posted $11.25 million of revenue versus published consensus of roughly $4.15 million and a $0.03 per-share loss versus roughly $0.06 expected. The key driver was $10.0 million of Novo development-milestone revenue, while INPEFA product revenue was only $1.2 million. The beat is real, but it is not evidence of a sudden commercial inflection: the milestone is non-recurring, and product revenue remains small.
| Q3 2026 | Q3 2025 | Consensus | |
|---|---|---|---|
| Total revenue (Financial Highlights) | $11.25M | $14.18M | ~$4.15M |
| Net product revenue (Financial Highlights) | $1.18M | $1.01M | |
| Net loss per share (Financial Highlights) | $(0.03) | $(0.04) | ~$(0.06) |
| Cash and investments (Balance Sheet Data) | $183.20M |
The operational update is constructive, but mostly execution rather than surprise. SONATA-HCM enrolled 542 patients, exceeding the planned size, and the reported baseline symptom burden supports a clinically relevant study population. 〔0〕 The more important remaining question is efficacy, with topline data still expected in the first quarter of 2027; enrollment itself was already announced in the prior quarter.
The ZYNQUISTA path is clearer, but not yet de-risked to approval. STENO1 has reached the patient-exposure and safety-data requirements needed to support an NDA resubmission, removing a procedural hurdle. 〔1〕 The filing still describes a planned resubmission, not an accepted filing or an FDA decision.
Liquidity supports the next milestones, but the business remains loss-making and financing-dependent over time. Cash and investments were $183.2 million at September 30, versus $125.2 million of cash, investments and restricted cash at year-end, largely reflecting the February equity raise. Operating expenses remain well above recurring product revenue, and the share count is materially higher than a year ago, so the stronger balance sheet came with dilution rather than operating self-sufficiency.
Bottom line: This is a clean earnings beat and a solid execution quarter, but the headline upside comes from a milestone payment while the core pipeline news largely confirms the existing plan. It modestly strengthens Lexicon’s near-term setup without changing the central wait for ZYNQUISTA resubmission and SONATA-HCM data.
ZYNQUISTA NDA resubmission and SONATA-HCM data, Q1 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!